ANAPTYSBIO, INC. Treasury Stock, Shares, Acquired
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- ANAPTYSBIO, INC. treasury stock, shares, acquired for the quarter ending 2025-12-31 was 100.02K shares.
- ANAPTYSBIO, INC. treasury stock, shares, acquired for the quarter ending 2025-09-30 was 490.23K shares.
- ANAPTYSBIO, INC. treasury stock, shares, acquired for the quarter ending 2025-06-30 was 2.56M shares.
- ANAPTYSBIO, INC. treasury stock, shares, acquired for the quarter ending 2025-03-31 was 292.90K shares, a 86.21% decline year-over-year.
- ANAPTYSBIO, INC. treasury stock, shares, acquired for fiscal 2025 was 3.44M shares.
- ANAPTYSBIO, INC. treasury stock, shares, acquired for fiscal 2023 was 2.12M shares.
| Period end | Treasury Stock, Shares, Acquired 3 month | Treasury Stock, Shares, Acquired 12 month |
|---|---|---|
| 2025-12-31 | 100.02K shares 10-K · filed 2026-03-03 | 3.44M shares 10-K · filed 2026-03-03 |
| 2025-09-30 | 490.23K shares 10-K · filed 2026-03-03 | |
| 2025-06-30 | 2.56M shares 10-K · filed 2026-03-03 | |
| 2025-03-31 | 292.90K shares 10-K · filed 2026-03-03 | |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | 2.12M shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | 2.12M shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-03-31 | 2.12M shares 10-Q · filed 2024-05-09 | 2.66M shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 2.12M shares 10-K · filed 2025-02-27 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | |
| 2023-06-30 | 534.79K shares 10-K · filed 2025-02-27 | |
| 2023-03-31 | 1.59M shares 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |